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Putting the magic in magic bullets: top three global
priorities for sexually transmitted infection control
Nicola Low,1 Sarah J Hawkes2
“Man is born, not to solve the problems of the
universe, but to find out where the problem applies,
and then to restrain himself within the limits of the
comprehensible.” Goethe, 1825
INTRODUCTION
Setting practical priorities for sexually transmitted
infection (STI) control is a balance between
idealism and pragmatism. Infections transmitted
through unsafe sex (chlamydia, gonorrhoea, syph-
ilis, HIV, hepatitis B and human papillomavirus
(HPV) infections) rank in the top five causes of the
global burden of disease.1 Their distribution in
populations is driven by a complex mixture of
individual behaviours, social and community
norms and societal and historical context. Ideally,
we would be able to reduce exposure to unsafe sex
to its theoretical minimum level of zero and thus
eliminate a significant proportion of the current
global burden of disease, particularly in resource-
poor settings.2 Ideally, we would have ‘magic
bullets’ for diagnosing and preventing STI in addi-
tion to specific antimicrobial agents for specific
infections.3 Arguably, we have ‘bullets’ that work
at the individual level; highly accurate diagnostic
tests and highly efficacious vaccines, antimicrobial
agents and preventive interventions.4 Introducing
them into populations to achieve similarly high
levels of effectiveness has been more challenging.4
In practice, the ‘magic’ in the magic bullet can be
seen as overcoming the barriers to sustainable
implementation in partnerships, larger sexual
networks and populations (figure 1).4 We have
chosen three (pragmatic) priorities for interven-
tions that we believe could be implemented and
scaled up to control STI other than HIV/AIDS. We
present these starting with the partnership and
moving up to the population level.
STRENGTHEN PARTNER NOTIFICATION
Strengthening the implementation and effective-
ness of partner notification has the potential to
contribute to the control of several STI. Partner
notification is done for different reasons and its use
and evaluation need to take these into consider-
ation. First, the prevalence of infection in sexual
partners who attend for testing is high, so partner
notification is efficient for case finding. Second,
partner notification can prevent re-infection from
an existing partner with a curable STI, in which
case the couple should not have unprotected sex
until the infection is eradicated. Ineffective partner
notification is one reason for the high levels of
repeated chlamydia observed after treatment.
Third, partner notification could interrupt the
onward transmission in a sexual network; a noti-
fied partner would then bring another infected
partner to treatment and avoid having sex until
their own infection is cleared.
The traditional debate focuses on whether sexual
partners should be informed by the index patient
(patient referral), a healthcare professional
(provider referral) or a combination in which the
provider takes responsibility for informing partners
if the index case is unable to (contract referral). In
practice, patient referral is preferred by both
patients and providers, and is often the only
affordable method available, particularly for the
most common STI managed outside specialist
health services. The content of patient referral is
rarely defined and, at its simplest, consists of advice
for the index patient at the end of a consultation,
such as ‘You should tell your partner(s) that they
need treatment too’. Sexual partner histories are
often not elicited, supporting materials are not
given and there might be no follow-up.5
Randomised controlled trials show that index
cases with gonorrhoea or chlamydia who are given
additional infection-specific written information
for their partner(s), receive additional counselling or
both are up to 50% less likely to have repeated
infections at follow-up than those receiving simple
patient referral.6 7 The effectiveness of these
enhancements is at least as good as that observed
for expedited partner therapy,6 which might not be
acceptable because of the risk that sexual partners
would miss out on access to preventive services.7 It
is possible that the additional benefits of both
enhanced patient referral and expedited partner
therapy in trials are related more to the more
intensive communication and interaction with the
patient than specific effects of the methods. Further
trials would therefore help to identify the essential
components of enhanced patient referral, including
the use of newer technologies such as text
messaging and the web, and determine their effec-
tiveness in resource-limited settings. Ideally, we
would like to have empirical data to show the
extent to which partner notification reduces the
prevalence or incidence of STI, but modelling
studies might be the only way to obtain this
information.8
A priority for improving partner notification
outcomes is the allocation of resources to imple-
ment it as an integral part of the case management
of STI. Clinical guidelines need to be actively
disseminated to all healthcare professionals who
diagnose and treat STI and include recommenda-
tions about appropriate contact periods, advice,
follow-up and protection of patient confidentiality.
At the same time, further work is needed to reduce
1Division of Clinical
Epidemiology and Biostatistics,
Institute of Social and
Preventive Medicine, University
of Bern, Bern, Switzerland




Professor Nicola Low, Division
of Clinical Epidemiology and






Accepted 15 September 2011
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://sti.
bmj.com/site/about/unlocked.
xhtml
ii44 Sex Transm Infect 2011;87:ii44eii46. doi:10.1136/sextrans-2011-050207
Supplement






































the barriers for providers in initiating partner notification
(including embarrassment and lack of training and time) and for
patients in informing and referring partners (including embar-
rassment, fear of relationship breakdown or partner violence,
and concerns about confidentiality).
IMPLEMENT ANTENATAL SYPHILIS SCREENING PROGRAMMES
Congenital syphilis is at least as important a cause of fetal and
perinatal mortality as HIV infection.9 Syphilis, however, rarely
achieves a position of salience within antenatal and child health
programmes, even though there are an estimated two million
women every year with active syphilis in pregnancy.9 Untreated
or inadequately treated syphilis in pregnancy is estimated to
result in adverse pregnancy outcomes in up to 69% of infected
women, including late abortion (after 16 weeks) or stillbirth in
25%, prematurity or low birth weight in 13%, neonatal death in
11% and clinical congenital syphilis in 20%.9 Most countries
have antenatal syphilis screening policies in place but imple-
mentation is poor. A major challenge is that few women in
higher prevalence areas (particularly in Africa) attend antenatal
clinics before 20 weeks’ gestation.10 Currently, it is estimated
that fewer than one in eight women receives syphilis testing at
any point in their pregnancy.11
We have the evidence to show the potential benefi ts of
antenatal syphilis screening interventions. Antenatal syphilis
screening interventions are a package of ‘bullets’ such as point-
of-care tests and single-dose antibiotic treatment that need to be
combined with: early antenatal clinic attendance; decentral-
isation and same-day treatment; partner notification; third
trimester retesting; and strengthening of health services to
provide supplies, training and monitoring. A meta-analysis of
randomised and non-randomised trials comparing a range of
interventions with usual care found reductions in perinatal
death and stillbirth due to syphilis of approximately 50%.11 The
incidence of congenital syphilis was also reduced but with
heterogeneous results. Women who have syphilis diagnosed in
pregnancy and treated with a single dose of long-acting peni-
cillin have the same rate of adverse pregnancy outcomes as
seronegative women.10 The exact combination of activities
needed to optimise effectiveness is not known.
There is already a WHO global initiative to eliminate
congenital syphilis, which is based on the guiding principles of
a country-driven, integrated, rights-based and collaborative
strategy. The four pillar strategy involves: (1) ensuring advocacy
and sustained political commitment for a successful health
initiative; (2) increasing access to, and quality of, maternal
and newborn health services; (3) screening and treating
pregnant women and partners; and (4) establishing surveillance,
monitoring and evaluation systems.9 Political support for the
elimination of congenital syphilis is growing in some regions, for
example, the Pan-American region, which has an integrated
strategy for the elimination of congenital HIV infection and
syphilis. A cornerstone of the strategy is to strengthen, integrate
and decentralise services so that the successes of implementing
the prevention of mother-to-child transmission of HIV can be
broadened to include simultaneous access to diagnosis and
treatment of syphilis in pregnancy.12 Nonetheless, there are still
challenges to ensuring effective implementation, including
universal access to early antenatal care, health systems
strengthening to ensure adequate resources (financial, human,
logistical) for screening, and raising awareness of congenital
syphilis among health workers and pregnant women and their
families.
DELIVER VACCINES AGAINST STI
Vaccines can protect individuals against infection or disease. To
achieve the coverage levels needed to realise population-level
benefits, however, vaccination needs to be delivered as an
organised programme. We now have two highly efficacious
vaccines that prevent the acquisition of hepatitis B and HPV
and, ultimately, liver cancer and high-grade precancerous lesions
of the cervix. Hepatitis B was estimated to have caused 2 million
disability-adjusted life-years and HPV-associated cervical
cancer another 3.7 million disability-adjusted life-years lost in
2004.1 The first hepatitis B vaccine was tested on men who have
sex with men in the 1970s but, paradoxically, was not subse-
quently strongly promoted for the prevention of STI.13 HPV
vaccines protecting against the two most common oncogenic
serotypes (16 and 18) were licensed in 2007 and are projected to
prevent up to 70% of cervical cancer cases, 80% of which occur
in developing countries.14 HPV vaccination has been taken up
rapidly, but in developed countries that already have strong
cervical cancer screening programmes and a low burden of
disease.
Universal hepatitis B vaccination in infancy is the only
strategy that will eliminate sexual transmission. WHO has
recommended this strategy since 1992 and it is now included in
national immunisation programmes in 164 countries. The rate
of chronic carriage has been substantially reduced in these
countries and reduced sexual transmission should be seen soon.
Some countries, including the UK, where the number of cases of
acute hepatitis B (approximately 700 a year) has not been
reduced, continue to recommend vaccination only for those at
high risk of infection or of complications of disease. Ongoing
transmission can continue with targeted vaccination because,
even though 90% of men who have sex with men attending
genitourinary medicine clinics have a first dose of hepatitis B
vaccine, only approximately 50% complete the course, and
many others who become infected through heterosexual sex
would not have been identified as being at high risk.
HPV vaccination is recommended by WHO as part of a coor-
dinated strategy to prevent all HPV-related disease.14 There are
major challenges for delivery to 11e14-year-old girls in settings
in which school attendance is low, to overcome concerns about
the use of a vaccine in children to prevent a STI, and to provide
the financing for a new and very expensive vaccine. Screening for
cervical cancer at older ages will also need to continue to detect
lesions caused by HPV serotypes not included in the vaccines.
The benefits are likely to be highest in developing countries with
a high disease burden where cervical cancer screening is poor,
Figure 1 Levels of action for sexually transmitted infection interven-
tions. Adapted from Low et al.4 PN, partner notification.
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such as India, which accounts for 25% of all cervical cancer cases
worldwide.15
CONCLUSION
The interventions prioritised here are of confirmed efficacy4 13
and all, apart from HPV vaccination, have been available for
decades at least. The effective implementation of partner noti-
fication and antenatal syphilis screening are ‘quick wins’, while
the population benefits of vaccination programmes for cancer
prevention will take longer to realise. These are pragmatic and
achievable interventions that could be implemented even in
resource-poor settings as long as there is sufficient political
commitment (including resource allocation) to tackling the
burden of STI. In an ideal world, we should also be working
to influence public policies to address the underlying drivers
of STI epidemics, including poverty, gender inequality and
lack of sexual rights. This will take time, resources and inter-
sectoral collaboration, for example, by forming partnerships
with the education, legal and employment sectors. With
commitment, organisation and delivery at the appropriate levels,
combinations of interventions will reduce the burden of STI
substantially.
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